Cytokinetics Inc
CYTK
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.18B
Close$
$-13.33
118.1% downside
Current Fair Value
118.1% downsideOvervalued by 118.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.18 Billion |
|---|---|
| Enterprise Value | $10.20 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.54 |
| Beta | 0.36 |
| Outstanding Shares | 132,086,000 |
Return
| Return on Equity | 515.31% |
|---|---|
| Return on Assets | -46.45% |
| Return on Invested Capital | -48.69% |
Valuation & Multiples
| P/E Ratio | -10.23 |
|---|---|
| PEG | -21.35 |
| Price to Sales | - |
| Price to Book Ratio | -36.89 |
| Enterprise Value to Revenue | 143.69 |
| Enterprise Value to EBIT | -12.01 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | -7.33 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-1.63
Average shareholder expectationRevenue Estimate
$17.59 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-1.47
Average shareholder expectationRevenue Estimate
$36.80 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1683▼ 22.84% |
|---|---|
| Total Calls | 6,357,200▼ 15.78% |
| Total Puts | 1,070,176▼ 64.27% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 130.76%▲ 12.25% |
|---|---|
| Total Invested | $13.91B▲ 44.50% |
| Investors Holding | 512▲ 19.00% |
ESG Score
No data
About Cytokinetics Inc
CEO: Robert Blum